Drugs / MC2 TCR T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04729543 | Oct 2020 → Dec 2024 overdue | uveal melanoma | Erasmus Medical Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MC2 TCR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04729543 ↗ |
| Known as | MAGE-C2/HLA-A2 TCR T cells | “safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).” NCT04729543 ↗ |
| Modality | Cell therapy | “T cell receptor-engineered T cells to treat solid tumors” PMID 25423330 ↗ Dec 2014 |
| Route | Intravenous | “one single intravenous administration of MC2 TCR T cells” NCT04729543 ↗ |
| Target | MAGEC2 | “the investigators target the Cancer Germline Antigen (CGA) MAGE-C2 (MC2)” NCT04729543 ↗ |